Want to see NRXP full AI Analyst Report?
NRXP Stock Chart & Stats
$2.55
-$0.69(-14.70%)
At close: 4:00 PM EST
$2.55
-$0.69(-14.70%)
Day’s Range― - ―
52-Week Range$1.62 - $5.06
Previous CloseN/A
Volume2.07M
Average Volume (3M)475.66K
Market Cap
$177.84M
Enterprise Value$63.07
Total Cash (Recent Filing)$6.71M
Total Debt (Recent Filing)$934.00K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 17, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding41,943,280
10 Day Avg. Volume509,446
30 Day Avg. Volume475,656
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$38.25Price Target Upside1400.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$13.89M
Bulls Say, Bears Say
Bulls Say
KETAFREE Regulatory & ManufacturingFDA's preliminary bioequivalence finding and reclassification to VAI, combined with a validated blow-fill-seal (BFS) process capable of ~1M units/week and a 1M-unit batch order, materially de-risks commercial manufacturing. This durable manufacturing scale and regulatory support improve launch readiness, margin potential and supply sovereignty versus compounding alternatives, strengthening long-term commercialization prospects.
NRX-100 NDA Backed By RWEA NDA supported by large real-world evidence (>65k patients) plus >1,000 clinical records and FDA engagement reduces single-trial regulatory risk and could accelerate labeling breadth (including suicidality). This durable evidentiary base strengthens the prospect of approval and payer discussions, improving the long-term commercial addressable market and revenue runway if approved.
HOPE Clinic Network & Tech IntegrationAn expanding clinic footprint plus AI monitoring and installed TMS capacity creates a direct-to-provider commercialization channel. Clinics generate revenue today and provide durable patient access and real-world data capture, aiding adoption, payer engagement and product differentiation versus compounded alternatives—an enduring advantage for market penetration.
Bears Say
Cash Burn & Negative EquitySustained multi-million-dollar operating losses and heavy free cash burn create a structural reliance on external capital and limit flexibility. Negative shareholders' equity signals an accumulated deficit that constrains balance-sheet options, increases dilution risk over time, and can impede sustained investment in commercialization and late-stage development.
Dependence On Equity FinancingFrequent capital raises and use of ATM/shelf offerings indicate operations are not yet self-funding. Reliance on equity dilutes existing holders, can shift management focus to financing cadence, and creates execution risk if market windows close—structural constraints that may impede timely commercialization or trial completion without predictable funding.
Regulatory, Funding & Execution Timing RisksKey programs face conditional timelines: final FDA actions, RWE statistical-plan agreement and dependence on nondilutive grants for trials create execution uncertainty. These structural timing risks can extend cash needs, delay revenue recognition, and complicate payer/distributor engagement, making long-term planning and commercialization outcomes less certain.
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.62 and its highest was $5.05 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $177.84M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Aug 17, 2026 which is in 30 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on May 18, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of $0.209 by -$0.249.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.11.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 41,943,280 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, missing expectations of $0.209. Following the earnings report the stock price went down -5.03%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.25 (1400.00% Upside)
$38.25 (1400.00% Upside)
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.80%
12-Months-Change
Fundamentals
Return on Equity
107.73%
Trailing 12-Months
Asset Growth
56.82%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
NRXP Stock 12 Month Forecast
Average Price Target
$38.25
▲(1400.00% Upside)
Technical Analysis
CervoMed
―
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
9.00%
Insiders
3.22% Mutual Funds
8.68% Other Institutional Investors
73.50% Public Companies and Individual Investors